AUTHOR INDEX

Volume 70 • 1996

Ajisawa, Y. *See* Yamazaki, Y.
Akahane, M. *See* Yamazaki, Y.
Akie, Y. *See* Xue, Y.X.
Akiyama, H. *See* Miyauchi, S.
Annoh, S. *See* Ueno, Y.
Azuma, Y. *See* Manabe, N.

Ban, T. *See* Sada, H.

Eto, K. *See* Xue, Y.X.

Fujii, E. *See* Muraki, T.
Fujioka, T., Nara, F., Shimada, Y., Fukushige, J., Shimotsu, H., Shigehara, E., Fukami, M. and Tsujita, Y.
Dosage regimens of pravastatin 329
Fujita, A., Takeuchi, T., Ishii, T., Nishio, H. and Hata, F.
Cooperation of ATP and norepinephrine 273
Fujita, K., Matsumura, Y., Miyazaki, Y., Takaoka, M. and Morimoto, S.
Endothelin-1 and DOCA-salt hypertension 313
Fukami, M. *See* Fujioka, T.
Fukunaga, Y. *See* Kishioka, S.
Fukushige, J. *See* Fujioka, T.
Fukuyama, J., Ichikawa, K., Miyazawa, K., Hamano, S., Shibata, N. and Ujiie, A.
Tranilast and intimal hyperplasia 321

Goto, K. *See* Shan, L.-H.

Hagihara, H. *See* Sakuma, Y.
Hamano, S. *See* Fukuyama, J.
Harris, R.A. *See* Klein, R.L.
Hashimoto, K. *See* Xue, Y.X.
Hata, F. *See* Fujita, A.
Hatakeyama, Y., Tomoi, M., Ohtsuka, M. and Shimomura, K.
Adaptive cytoprotection and sensory neurons 347
Hattori, T., Nagamatsu, T., Ito, M. and Suzuki, Y.
Mononuclear cells in PAN nephrosis 25
Hayashi, J. *See* Kamiyama, T.
Hayashi, K., Nagamatsu, T., Honda, S. and Suzuki, Y.
Antinephritic effect of butein 55
Hayashi, K., Nagamatsu, T., Ito, M. and Suzuki, Y.
Antinephritic effect of FK506 43
Hayashi, K., Nagamatsu, T., Ito, M., Yagita, H. and Suzuki, Y.
Suppression of ICAM-1 expression 157
Hirano, M. *See* Nagano, N.
Honda, S. *See* Hayashi, K.
Horikawa, H. *See* Muraki, T.
Huang, N.-L. *See* Manabe, N.

Ichikawa, K. *See* Fukuyama, J.
Ichimura, M. *See* Kato, Y.
Ikegami, Y., Yano, S. and Nakao, K.
Effect of CGP41251 on human NSCLC 65
Imaizumi, Y. *See* Nagano, N.
Imaoka, T. *See* Miyauchi, S.
Inoue, N. *See* Kishioka, S.
Inoue, R. *See* Yamada, K.
Irie, K. *See* Muraki, T.
Ishii, T. *See* Fujita, A.
Isohama, Y. *See* Tai, S.
Ito, M. *See* Hattori, T.
—— *See* Hayashi, K.
Ito, Yoshikuni *See* Sakuma, Y.
Ito, Yushi *See* Yamada, K.

Kai, H. *See* Tai, S.
Kamada, H. and Nakagami, K.
Effect of mizoribine on collagen arthritis 169
Kamata, K., Kojima, S., Sugiura, M. and Kasuya, Y.
LDL and endothelium 149
Kamiyama, T., Tanonaka, K., Hayashi, J. and Takeo, S.
Aprindine and ischemic/reperfused heart 227
Kasuya, Y. *See* Kamata, K.
Kato, Y. *See* Tanaka, H.
Kato, Y., Mori, T., Ohmori, K. and Ichimura, M.
Effect of KW-4679 on action potential 199
Katori, M. and Majima, M.
Renal kallikrein and hypertension 95
Kawaguchi, T. *See* Miyauchi, S.
Kawanishi, T. *See* Tanaka, H.
Kawasaki, H., Manabe, H. and Ohmori, K.
KW-4679 inhibits hyperresponsiveness 277
Kimura, S. *See* Shan, L.-H.
Kinjo, N. *See* Manabe, N.
Kishioka, S., Inoue, N., Nishida, S., Fukunaga, Y. and Yamamoto, H.
Amount of morphine infused and dependence 17
Kitada, Y.
Betaxolol and Ca^{2+} sensitivity 191
Klein, R.L. and Harris, R.A.
$GABA_A$ receptor regulation 1
Kobayashi, M. *See* Yamazaki, Y.
Kohno, S. *See* Nabe, T.
Koike, H. *See* Ueno, Y.
Kojima, S. *See* Kamata, K.

Majima, M. *See* Katori, M.
Manabe, H. *See* Kawasaki, H.
Manabe, N., Sugimoto, M., Azuma, Y., Taketomo, N., Yamashita, A., Tsuboi, H., Tsunoo, A., Kinjo, N., Huang, N.-L. and Miyamoto, H.
In vivo liver energy metabolism 85
Masaki, T. *See* Shan, L.-H.
Masuda, Y., Yoshizawa, T., Ozaki, M. and Tanaka, Toshimitsu
Oxethazaine action on the liver 243
Matsuki, N. *See* Tanaka, Tatsuro
Matsumoto, M. *See* Saito, Hideya
Matsumura, Y. *See* Fujita, K.
Miyamoto, H. *See* Manabe, N.
Miyata, T. *See* Tai, S.
Miyauchi, S., Imaoka, T., Okada, T., Motoyama, M., Kawaguchi, T., Akiyama, H. and Odomi, M.
Increase of 5-fluorouracil by BOF-A2 139
Miyazaki, Y. *See* Fujita, K.
Miyazawa, K. *See* Fukuyama, J.
Mori, T. *See* Kato, Y.
Morimoto, S. *See* Fujita, K.
Moroi, K. *See* Shan, L.-H.
Motoyama, M. *See* Miyauchi, S.

AUTHOR INDEX

Volume 70 • 1996

Ajisawa, Y. *See* Yamazaki, Y.
Akahane, M. *See* Yamazaki, Y.
Akie, Y. *See* Xue, Y.X.
Akiyama, H. *See* Miyauchi, S.
Annoh, S. *See* Ueno, Y.
Azuma, Y. *See* Manabe, N.

Ban, T. *See* Sada, H.

Eto, K. *See* Xue, Y.X.

Fujii, E. *See* Muraki, T.
Fujioka, T., Nara, F., Shimada, Y., Fukushige, J., Shimotsu, H., Shigehara, E., Fukami, M. and Tsujita, Y.
Dosage regimens of pravastatin 329
Fujita, A., Takeuchi, T., Ishii, T., Nishio, H. and Hata, F.
Cooperation of ATP and norepinephrine 273
Fujita, K., Matsumura, Y., Miyazaki, Y., Takaoka, M. and Morimoto, S.
Endothelin-1 and DOCA-salt hypertension 313
Fukami, M. *See* Fujioka, T.
Fukunaga, Y. *See* Kishioka, S.
Fukushige, J. *See* Fujioka, T.
Fukuyama, J., Ichikawa, K., Miyazawa, K., Hamano, S., Shibata, N. and Ujiie, A.
Tranilast and intimal hyperplasia 321

Goto, K. *See* Shan, L.-H.

Hagihara, H. *See* Sakuma, Y.
Hamano, S. *See* Fukuyama, J.
Harris, R.A. *See* Klein, R.L.
Hashimoto, K. *See* Xue, Y.X.
Hata, F. *See* Fujita, A.
Hatakeyama, Y., Tomoi, M., Ohtsuka, M. and Shimomura, K.
Adaptive cytoprotection and sensory neurons 347
Hattori, T., Nagamatsu, T., Ito, M. and Suzuki, Y.
Mononuclear cells in PAN nephrosis 25
Hayashi, J. *See* Kamiyama, T.
Hayashi, K., Nagamatsu, T., Honda, S. and Suzuki, Y.
Antinephritic effect of butein 55
Hayashi, K., Nagamatsu, T., Ito, M. and Suzuki, Y.
Antinephritic effect of FK506 43
Hayashi, K., Nagamatsu, T., Ito, M., Yagita, H. and Suzuki, Y.
Suppression of ICAM-1 expression 157
Hirano, M. *See* Nagano, N.
Honda, S. *See* Hayashi, K.
Horikawa, H. *See* Muraki, T.
Huang, N.-L. *See* Manabe, N.

Ichikawa, K. *See* Fukuyama, J.
Ichimura, M. *See* Kato, Y.
Ikegami, Y., Yano, S. and Nakao, K.
Effect of CGP41251 on human NSCLC 65
Imaizumi, Y. *See* Nagano, N.
Imaoka, T. *See* Miyauchi, S.
Inoue, N. *See* Kishioka, S.
Inoue, R. *See* Yamada, K.
Irie, K. *See* Muraki, T.
Ishii, T. *See* Fujita, A.
Isohama, Y. *See* Tai, S.
Ito, M. *See* Hattori, T.
—— *See* Hayashi, K.
Ito, Yoshikuni *See* Sakuma, Y.
Ito, Yushi *See* Yamada, K.

Kai, H. *See* Tai, S.
Kamada, H. and Nakagami, K.
Effect of mizoribine on collagen arthritis 169
Kamata, K., Kojima, S., Sugiura, M. and Kasuya, Y.
LDL and endothelium 149
Kamiyama, T., Tanonaka, K., Hayashi, J. and Takeo, S.
Aprindine and ischemic/reperfused heart 227
Kasuya, Y. *See* Kamata, K.
Kato, Y. *See* Tanaka, H.
Kato, Y., Mori, T., Ohmori, K. and Ichimura, M.
Effect of KW-4679 on action potential 199
Katori, M. and Majima, M.
Renal kallikrein and hypertension 95
Kawaguchi, T. *See* Miyauchi, S.
Kawanishi, T. *See* Tanaka, H.
Kawasaki, H., Manabe, H. and Ohmori, K.
KW-4679 inhibits hyperresponsiveness 277
Kimura, S. *See* Shan, L.-H.
Kinjo, N. *See* Manabe, N.
Kishioka, S., Inoue, N., Nishida, S., Fukunaga, Y. and Yamamoto, H.
Amount of morphine infused and dependence 17
Kitada, Y.
Betaxolol and Ca^{2+} sensitivity 191
Klein, R.L. and Harris, R.A.
$GABA_A$ receptor regulation 1
Kobayashi, M. *See* Yamazaki, Y.
Kohno, S. *See* Nabe, T.
Koike, H. *See* Ueno, Y.
Kojima, S. *See* Kamata, K.

Majima, M. *See* Katori, M.
Manabe, H. *See* Kawasaki, H.
Manabe, N., Sugimoto, M., Azuma, Y., Taketomo, N., Yamashita, A., Tsuboi, H., Tsunoo, A., Kinjo, N., Huang, N.-L. and Miyamoto, H.
In vivo liver energy metabolism 85
Masaki, T. *See* Shan, L.-H.
Masuda, Y., Yoshizawa, T., Ozaki, M. and Tanaka, Toshimitsu
Oxethazaine action on the liver 243
Matsuki, N. *See* Tanaka, Tatsuro
Matsumoto, M. *See* Saito, Hideya
Matsumura, Y. *See* Fujita, K.
Miyamoto, H. *See* Manabe, N.
Miyata, T. *See* Tai, S.
Miyauchi, S., Imaoka, T., Okada, T., Motoyama, M., Kawaguchi, T., Akiyama, H. and Odomi, M.
Increase of 5-fluorouracil by BOF-A2 139
Miyazaki, Y. *See* Fujita, K.
Miyazawa, K. *See* Fukuyama, J.
Mori, T. *See* Kato, Y.
Morimoto, S. *See* Fujita, K.
Moroi, K. *See* Shan, L.-H.
Motoyama, M. *See* Miyauchi, S.

Muraki, T., Fujii, E., Okada, M., Horikawa, H., Irie, K. and Ohba, K.
Vascular permeability and iNOS inhibitor 269
Mutoh, S. *See* Sakuma, Y.

Nabe, T., Yamamura, H. and Kohno, S.
Eosinophils in sensitized guinea pigs 337
Nagamatsu, T. *See* Hattori, T.
—— *See* Hayashi, K.
Nagano, N., Imaizumi, Y., Hirano, M. and Watanabe, M.
NDGA as an opener of BK channels 281
Nagao, T. *See* Yamazaki, J.
Nagayoshi, A. *See* Sakuma, Y.
Nakagami, K. *See* Kamada, H.
Nakamura, R. *See* Tanaka, H.
Nakamura, Y. *See* Ueno, Y.
Nakao, K. *See* Ikegami, Y.
Nara, F. *See* Fujioka, T.
Naraba, H. *See* Ueno, A.
Nishida, S. *See* Kishioka, S.
Nishio, H. *See* Fujita, A.
Nishio, S. *See* Ueno, Y.
Nishiyama, M. *See* Shan, L.-H.
Notsu, Y. *See* Sakuma, Y.

Obata, Y. *See* Yokota, K.
Ochi, Y. *See* Ueno, Y.
Oda, M. *See* Yokota, K.
Odomi, M. *See* Miyauchi, S.
Ogawa, N. *See* Ohdo, S.
Oh-ishi, S. *See* Ueno, A.
Ohba, K. *See* Muraki, T.
Ohdo, S., Watanabe, H., Ogawa, N., Yoshiyama, Y. and Sugiyama, T.
Chronoembryotoxicity of sodium valproate 253
Ohmori, K. *See* Kato, Y.
—— *See* Kawasaki, H.
Ohne, K. *See* Sakuma, Y.
Ohtsuka, M. *See* Hatakeyama, Y.
Okada, M. *See* Muraki, T.
Okada, T. *See* Miyauchi, S.
Okuhara, M. *See* Sakuma, Y.
Ozaki, M. *See* Masuda, Y.

Sada, H., Ban, T. and Sperelakis, N.
Taurine and action potential duration 303
Saito, Hideya, Matsumoto, M., Togashi, H. and Yoshioka, M.
Serotonin and neurotransmitters 203
Saito, Hiroshi *See* Tanaka, Tatsuro
Sakuma, Y., Hagihara, H., Ohne, K., Nagayoshi, A., Mutoh, S., Ito, Yoshikuni, Notsu, Y. and Okuhara, M.
FR129169 reduced plasma cholesterol 35
Sawada, T. *See* Takagi, J.
Shan, L.-H., Nishiyama, M., Shibasaki, T., Moroi, K., Goto, K., Masaki, T. and Kimura, S.
ET_A and ET_B receptors mediate relaxation 259
Shibasaki, T. *See* Shan, L.-H.
Shibata, N. *See* Fukuyama, J.
Shigehara, E. *See* Fujioka, T.
Shigenobu, K. *See* Tanaka, H.
Shimada, Y. *See* Fujioka, T.
Shimomura, K. *See* Hatakeyama, Y.
Shimotsu, H. *See* Fujioka, T.
Sperelakis, N. *See* Sada, H.
Sugimoto, M. *See* Manabe, N.
Sugiura, M. *See* Kamata, K.
Sugiyama, T. *See* Ohdo, S.
Suzuki, Y. *See* Hattori, T.
—— *See* Hayashi, K.

Tai, S., Kai, H., Isohama, Y., Takahama, K. and Miyata, T.
LTD_4 and tracheal mucociliary transport 195
Takagi, J., Sawada, T. and Yonehara, N.
Monoaminergic systems and acupuncture 73
Takahama, K. *See* Tai, S.
Takaoka, M. *See* Fujita, K.
Takeda, H. *See* Yamazaki, Y.
Takeo, S. *See* Kamiyama, T.
Taketomo, N. *See* Manabe, N.
Takeuchi, T. *See* Fujita, A.
Tanaka, H., Kawanishi, T., Kato, Y., Nakamura, R. and Shigenobu, K.
Nuclear $[Ca^{2+}]$ images in cardiomyocytes 235
Tanaka, Tatsuro, Saito, Hiroshi and Matsuki, N.
Ca^{2+} oscillation in neurons 89
Tanaka, Toshimitsu *See* Masuda, Y.
Tanonaka, K. *See* Kamiyama, T.
Togashi, H. *See* Saito, Hideya
Tokumasu, T. *See* Ueno, A.
Tomoi, M. *See* Hatakeyama, Y.
Tsuboi, H. *See* Manabe, N.
Tsujita, Y. *See* Fujioka, T.
Tsunoo, A. *See* Manabe, N.

Ueno, A., Tokumasu, T., Naraba, H. and Oh-ishi, S.
LPS-induced vascular permeability of rat 285
Ueno, Y., Koike, H., Nakamura, Y., Ochi, Y., Annoh, S. and Nishio, S.
Effects of BPS on diabetic neuropathy 177
Ujiie, A. *See* Fukuyama, J.
Urushidani, T. *See* Yamazaki, J.

Waniishi, Y. *See* Yamada, K.
Watanabe, H. *See* Ohdo, S.
Watanabe, M. *See* Nagano, N.

Xue, Y.X., Eto, K., Akie, Y. and Hashimoto, K.
Sematilide on ventricular arrhythmias 129

Yagita, H. *See* Hayashi, K.
Yamada, K., Waniishi, Y., Inoue, R. and Ito, Yushi
Cation channel agonist in smooth muscle 81
Yamamoto, H. *See* Kishioka, S.
Yamamoto, N. *See* Yokota, K.
Yamamura, H. *See* Nabe, T.
Yamashita, A. *See* Manabe, N.
Yamazaki, J., Urushidani, T. and Nagao, T.
Activation of NO synthase by barium 351
Yamazaki, Y., Akahane, M., Kobayashi, M., Takeda, H. and Ajisawa, Y.
KSG-504 and rat pancreatic secretion 183
Yano, S. *See* Ikegami, Y.
Yokota, K., Yamamoto, N., Obata, Y. and Oda, M.
Effect of KBT-3022 on neutrophil function 291
Yonehara, N. *See* Takagi, J.
Yoshioka, M. *See* Saito, Hideya
Yoshiyama, Y. *See* Ohdo, S.
Yoshizawa, T. *See* Masuda, Y.

SUBJECT INDEX

Volume 70 • 1996

Acteoside 157
Action potential 199, 303
Acyl-CoA: cholesterol acyltransferase 35
Adaptive cytoprotection 347
Adhesion molecule-1 (intercellular) 43, 157
Airway hyperresponsiveness 277
Alcohol 1
γ-Aminobutyric acid type A ($GABA_A$) receptor 1
Antiallergic drug 199
Antiarrhythmic action 303
Antiarrhythmic agent (class Ib) 227
Anti-GBM nephritis (crescentic type) 43, 55, 157
Anti-platelet drug 291
Apamin 259
Aprindine 227
Arrhythmia (reperfusion) 129
Arrhythmia (ventricular) 129
Arthritis (collagen-induced) 169
Atherosclerosis 35
ATP 273
Autoreceptor 203

Balloon injury 321
Barbiturate 1
Barium 351
Benzodiazepine 1
Beraprost sodium 177
Betaxolol 191
BOF-A2 (emitefur) 139
Bradykinin 285
Butein 55
BV-araU (sorivudine) 139

Ca^{2+} channel 303
Ca^{2+}-dependent K^+ channel 281
Ca^{2+} sensitivity 191
Ca^{2+} sensitization 273
Calcium ion 235
Calcium overload 227
Calmodulin 351
Cardiovascular hypertrophy 313
Cation channel opener 81
CD4-positive cell 55
CD8-positive cell 55
Cell cycle 65
Cellular immunity 25, 169
CGP41251 (4′-*N*-benzoyl staurosporine) 65
Chloride channel 1
Cholecystokinin 183
Cholesterol absorption 35
Chronotoxicity 253
Collagen-induced arthritis 169
Confocal microscopy 235
Cooperation of ATP and norepinephrine 273
Coronary arterial smooth muscle 281
Cuff treatment 321
Cytoprotection (adaptive) 347

Deoxycorticosterone acetate (DOCA)-salt hypertension 313
Dependence 1
Dosing regimen 329

Electrical stimulation (programmed) 129
Electro-acupuncture 73
Embryotoxicity 253
Emitefur (BOF-A2: 3-{3-[6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl]benzoyl}-1-ethoxymethyl-5-fluorouracil) 139
Endocrine secretion 183
Endothelial cell 157
Endothelin and receptor 259
Endothelin ET_A receptor 313
Endothelin-1 313
Endothelium 149
Endotoxin 285
Eosinophil 337
Evoked potential 73
Exocrine secretion 183

Fenamate 81
FK506 (tacrolims hydrate) 43
5-Fluorouracil-derived drug 139
Formyl-methionyl-leucyl-phenylalanine (fMLP) 291
FR129169 (*N*-(1,2-diphenylethyl)-2-octyloxy-phenylacetamide) 35
FR139317 ((*R*)2-[(*R*)-2-[(*S*)-2-[[1-(hexahydro-1*H*-azepinyl)]-carbonyl]amino-4-methyl-pentanoyl]amino-3-[3-(1-methyl-1*H*-indolyl)]propionyl]amino-3-(2-pyridyl)-propionic acid) 313

G2/M arrest 65
Glutamatergic neurotransmission 89

Hemodynamic effect 243
Hepatic microcirculation 243
Hepatocyte (rabbit) 329
Heteroreceptor 203
Human non-small cell lung cancer 65
Hypercholesterolemia 35
Hyperlipidemia 25
Hypertension 95, 313
Hypertrophy (cardiovascular) 313

Ileal smooth muscle (guinea pig) 259
Immunoblotting 329
Immunomodulator 169
Indo-1 235
Inducible nitric oxide synthase 269
Intercellular adhesion molecule-1 43, 157
Interleukin-2 43
Intimal hyperplasia 321
Intravenous morphine infusion 17
Ischemia 129
Ischemia/reperfusion 227

K^+ channel 303
K^+ channel (Ca^{2+}-dependent) 281
Kallikrein (renal) 95
KBT-3022 (ethyl 2-[4,5-bis-(4-methoxy-phenyl)thiazol-2-yl]pyrrol-1-ylacetate) 291
Kinin (urinary) 95
Kininogen 95
KSG-504 ((*S*)-arginium (*R*)-4-[*N*-(3-methoxy-propyl)-*N*-pentylcarbamoyl]-5-(2-naphthyl-sulfonyl) pentanoate monohydrate) 183
KW-4679 ((*Z*)-11-[(3-dimethylamino)propyl-idene]-6,11-dihydrodibenz[*b*,*e*]oxepin-2-acetic acid monohydrochloride) 277

Leukocyte 43
Leukopenia 139
Leukotriene B_4 291
Leukotriene D_4 195
Lipopolysaccharide 269
Liver (perfused rat) 243
Liver energy state 85
Low-density lipoprotein (LDL) 149
Low-density lipoprotein (LDL) receptor 329
Lung cancer (human non-small cell) 65
Lysophosphatidylcholine (LPC) 149

Metabolic effect 243
Microcirculation (hepatic) 243
Microdialysis 203
Mizoribine 169
Morphine infusion 17
Morphological analysis 177
Motor nerve conduction velocity 177
Myocardium 235
Myocyte (ventricular) 199

Naloxone-precipitated withdrawal 17
Nephrosis 25
Nerve blood flow 177
Neurotransmission (glutamatergic) 89
Neutrophil (rabbit) 291
Neutrophil (rat) 157
Nitric oxide 347
Nitric oxide synthase 351
Nitric oxide synthase (inducible) 269
non-NMDA receptor 89
Nordihydroguaiaretic acid 281
Norepinephrine 273
Nuclear magnetic resonance (NMR) 85
Nucleus 235

ONO-1078 (pranlukast: 4-oxo-8-[4-(4-phenyl-butoxy)-benzoylamino]-2-(tetrazol-5-yl)-4*H*-1-benzopyran) 195
Oxethazaine 243

Pancreas (rat) 183
Perfused rat liver 243

Phosphorus-31 nuclear magnetic resonance (^{31}P NMR) (in vivo) 85
Plasma morphine concentration 17
Platelet-activating factor 285
Portal vein smooth muscle 81
Pranlukast (ONO-1078) 195
Pravastatin 149, 329
Prazosin 149
Programmed electrical stimulation 129
Prostaglandin 285
Protein kinase C inhibitor 65
Psychiatric disorder 203
Puromycin aminonucleoside 25

Rabbit neutrophil 291
Receptor expression 1
Relaxation 259
Renal kallikrein 95
Reperfusion arrhythmia 129
Sematilide 129
Sensitization 337
Sensory neuron 347
Sephadex 337
Serotonin 73, 203
Skinned smooth muscle 191
Smooth muscle (guinea pig ileum) 259
Smooth muscle (porcine coronary artery) 281
Smooth muscle (rabbit portal vein) 81
Smooth muscle (skinned canine renal artery) 191
Smooth muscle cell (vascular) 321
Sodium accumulation 95
Sodium overload 227
Sodium valproate 253
Sorivudine (BV-araU: 1-β-D-arabino-furanosyl-(*E*)-5-(2-bromovinyluracil)) 139
Steroid 169
Superoxide anion 337
Synapse formation 89

Tacrolims hydrate (FK506) 43
Taurine 303
Thromboxane B_2 337
Tooth pulp stimulation 73
Tracheal mucociliary transport 195
Tranilast 321
Transfection 1
Trigeminal nucleus caudalis 73

Urinary kinin 95

Vas deferens (guinea pig) 273
Vascular permeability 269, 285
Vascular smooth muscle cell 321
Ventricular arrhythmia 129
Ventricular myocyte 199